Navigation Links
Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
Date:6/30/2009

ssels, inhibiting tumor growth and proliferation. In addition, a growing body of evidence supports the active role of PS in immune signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second immunostimulatory mechanism. Further information on the role of exposed PS in the tumor environment can be found in the Anti-PS Technical Backgrounder posted at www.peregrineinc.com.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company may not h
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Angeles, CA (PRWEB) May 04, 2015 ... Sands, is now offering a more comfortable and attractive ... the restoration of choice for those who have lost ... Dentures can feel insecure or slip at the worst ... patient eats or talks. They can also painfully pinch ...
(Date:5/4/2015)... 2015 CCL, a top-ranked, global provider ... program to other leadership development consultancies. “The CCL ... and successful practitioners, expanding our capacity to drive results ... John R. Ryan, CCL President and CEO. , As ... Partner Network , it will schedule a one-on-one conference ...
(Date:5/4/2015)... 2015 Dr. Benjamin Stong of Kalos ... the latest non-surgical double-chin eliminator. Dr. Stong is ... in Atlanta to offer Kybella treatments . The ... specifically under the chin, promising to safely dissolve fat ... patients who sought immediate solutions for their double chin ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Dr. Richard ... has been chosen to receive the America’s Best Dentist ... Dr. Champagne’s selection as a top dentist is a ... to continuing education and his compassion for his patients. ... professionals who exemplify excellence in their field. These nominees ...
(Date:5/4/2015)... 04, 2015 For partners who’d like ... lubricant -- Astroglide TTC™ (Trying to Conceive) . ... alter pH levels, Astroglide TTC™ is specially formulated to ... to the Centers for Disease Control, an average of ... pregnant or sustaining a pregnancy, and over 7.4 ...
Breaking Medicine News(10 mins):Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3
... Dental Research (AADR) has announced David C. Johnsen, dean of ... of the 2010 AADR Jack Hein Public Service Award. This ... Annual Meeting & Exhibition in Washington, DC, March 3, 2010. ... National Institutes of Health and the National Institute of Dental ...
... The American Association for Dental Research (AADR) is ... Harkin will be recognized at the AADR/Research!America Advocacy Day, ... is being recognized for his commitment to the National ... Dental and Craniofacial Research (NIDCR). He remains one of ...
... Pay-for-performance (P4P) programs are payment models that reward workers ... In the healthcare setting, P4P programs use a variety ... including fee differentials and bonuses. A new ... reveals that P4P programs appear to be effective in ...
... In a national poll aimed at helping with planning ... bioterrorism attack, researchers at the Harvard School of Public ... fictional scenario describing a significant anthrax attack in their ... public health recommendations to obtain prophylactic antibiotics. However, a ...
... ... engine marketing firm was featured in a national study of high performance services firms entitled ... Market.” , ... (PRWEB) February 19, 2010 -- Webmarketing 123, a San Francisco Bay Area based search engine ...
... to new treatments, study suggests , FRIDAY, Feb. 19 (HealthDay ... fibrosis, U.S. researchers have identified a defective signaling pathway that ... Cystic fibrosis causes thick, sticky mucus to build up in ... most common potentially lethal genetic diseases in children and young ...
Cached Medicine News:Health News:AADR presents honorary membership to Senator Tom Harkin 2Health News:Poll: Hypothetical anthrax attack and antibiotics 2Health News:Poll: Hypothetical anthrax attack and antibiotics 3Health News:Poll: Hypothetical anthrax attack and antibiotics 4Health News:Poll: Hypothetical anthrax attack and antibiotics 5Health News:Poll: Hypothetical anthrax attack and antibiotics 6Health News:Webmarketing 123 Profiled in National Study of High Growth Professional Services Firms 2Health News:Webmarketing 123 Profiled in National Study of High Growth Professional Services Firms 3Health News:Drug Improved Survival in Mice With Cystic Fibrosis 2
(Date:5/4/2015)... 4, 2015   HeartWare International, Inc . (NASDAQ: ... support technologies that are revolutionizing the treatment of advanced heart ... , is scheduled to present at the Bank of America ... Vegas on Thursday, May 14, 2015, at 10:00 ... of the Company,s presentation at the conference will be available ...
(Date:5/4/2015)... 4, 2015 Unchained Labs, a refreshingly new ... year,s PEGS conference and launches the UNit — the ... PEGS: The Essential Protein Engineering Summit takes place in ... The UNit lets drug discovery researchers look at ... there. Its 7 applications, 144 sample a day throughput ...
(Date:5/4/2015)... 2015 Intarcia Therapeutics, Inc. ... into the newly created role of Chief ... pharmaceutical executive with world-class experience – most recently ... service at industry leaders such as Pfizer and ... range of therapeutic areas, including: cardiovascular, metabolic, oncology, ...
Breaking Medicine Technology:HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2Unchained Labs Lets the UNit Loose 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 2Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 3Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S. 4
... survey of 137 healthcare providers show high satisfaction for ... ® Radiation Oncology / MOSAIQ ® Medical ... OIS—earned the top ranking. In addition, 88 percent of ... In the KLAS 2010 report , titled ...
... Oct. 6 GenVec, Inc. (Nasdaq: GNVC ... first option period (year two) under a previously announced ... and HIV vaccines in support of the Vaccine Research ... Infectious Diseases (NIAID), part of the National Institutes of ...
Cached Medicine Technology:Healthcare Providers Rate Elekta's MOSAIQ Oncology Information System as No. 1 in 2010 KLAS Report 2Healthcare Providers Rate Elekta's MOSAIQ Oncology Information System as No. 1 in 2010 KLAS Report 3GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development 2GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: